The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Page 8
athy, or thrombocytopenia, and between the currently used
rubella vaccine (RA 27/3) and radiculoneuritis and other
neuropathies or thrombocytopenic purpura;
· that the evidence does not
indicate a causal relation between DPT vaccine and infantile
spasms, hypsarrythmia, Reye syndrome, or SIDS;
· that the evidence is
consistent with a causal relation between DPT vaccine and acute
encephalopathy and shock and "unusual shock-like state," and
between RA 27/3 rubella vaccine and chronic arthritis; and
· that the evidence indicates
a causal relation between DPT vaccine and anaphylaxis, between the
pertussis component of DPT vaccine and protracted, inconsolable
crying, and between RA 27/3 rubella vaccine and acute
arthritis.1
RESEARCH NEEDS
In the course of its review, the committee encountered many gaps
and limitations in knowledge bearing directly and indirectly on the
safety of vaccines. These include inadequate understanding of the
biologic mechanisms underlying adverse events following natural
infection or immunization, insufficient or inconsistent information
from case reports and case series, inadequate size or length of
follow-up of many population-based epidemiologic studies, and
limited capacity of existing surveillance systems of vaccine injury
to provide persuasive evidence of causation. The committee found
few experimental studies published in relation to the number of
epidemiologic studies published. Clearly, if research capacity and
accomplishment in these areas are not improved, future reviews of
vaccine safety will be similarly handicapped.
With respect to pertussis and rubella vaccines, careful review
is needed to identify what sorts of questions might be best
answered by further investigations and which kinds of studies could
be carried out economically. The availability and introduction of
new forms of pertussis vaccine, for example, could offer valuable
opportunities for comparison of vaccine safety as well as efficacy.
The committee's experience points to fresh possibilities and to the
need for such a review.